OptiLight First Look: A Difference-Maker for Doctors and Dry Eye Patients

As an early adopter, Art Epstein, OD explains his first impressions of the new OptiLight and why he feels it’s a difference-maker for doctors and dry eye patients alike.

Lumenis Unveils a Wide Range of Innovative Technologies for Multiple Skin and Body Applications at the 2019 American Academy of Dermatology (AAD) Conference

Lumenis Unveils a Wide Range of Innovative Technologies for Multiple Skin and Body Applications at the 2019 American Academy of Dermatology (AAD) Conference

How it works

Vacuum gently draws skin into the handpiece, skin is stretched thin and target is pulled closer to the energy source. Energy is applied to target in which melanocytes are spread apart and blood flow is constricted. Target is damaged and skin is released.

Lumenis Proudly Showcases a Wide Range of Technologies for Multiple Skin & Body Applications at the 24th World Congress of Dermatology (WCD) 2019

Lumenis showcasing a wide range of novel technologies for skin, hair, body and women’s health applications at this year’s WCD, 11th – 14th June.

Digital Duet in Togo: Insights from an Unforgettable Clinical and Professional Journey

In Africa, glaucoma presents a uniquely difficult problem, as its high prevalence is compounded by economic barriers to essential medical care. Selective laser trabeculoplasty (SLT) is a potentially transformative modality in this setting, presenting an opportunity for quick, safe, and effective long-term treatment. During a trip to Togo, West Africa, Dr.Shlomo Melamed, MD and his colleagues taught local ophthalmologists to perform SLT using Digital Duet.

Getting the Very First OptiLight: A Perfect Fit for My Tech-Forward Practice

Jennifer Tsai, OD, has a tech-forward practice—the first to offer the easy-to-use, rapid-ROI OptiLight for effective management of dry eye disease.

Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLight™

Lumenis Ltd., the world’s largest energy-based medical device company for ophthalmic, aesthetic and surgical applications and the inventor of intense pulsed light (IPL) technology, today announced that the FDA has granted De Novo authorization for Lumenis’ newest IPL device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD).

The technology behind the DESIRE

Great clinical results begin with the LightSheer DESIRE 805 nm diode laser empowered by two advanced technologies Vacuum Assisted High-Speed Integrated Technology A large 22×35 mm spot size enables the use of low-fluence and with a unique mechanism for pain reduction provides effective, fast and comfortable treatment. ChillTip™ Technology – Integrated contact cooling provides epidermal protection for treatment areas requiring precision and higher fluence.

Significantly Improved Signs of Dry Eye Disease: Key Findings from FDA Study of Lumenis Light Therapy

The strongest affirmation of safety and efficacy- Dr. Steven Dell shares clinical benefits of Lumenis dry eye light therapy that…

IPL for Dry Eye

Intense Pulsed Light (IPL) for dry eyes: a non-invasive solution targeting Meibomian Gland Dysfunction (MGD) to improve eye comfort, vision & quality of life.